人乳头瘤病毒疫苗接种:免疫做法咨询委员会的建议。

IF 33.7 1区 医学 Q1 Medicine
Mmwr Recommendations and Reports Pub Date : 2014-08-29
Lauri E Markowitz, Eileen F Dunne, Mona Saraiya, Harrell W Chesson, C Robinette Curtis, Julianne Gee, Joseph A Bocchini, Elizabeth R Unger
{"title":"人乳头瘤病毒疫苗接种:免疫做法咨询委员会的建议。","authors":"Lauri E Markowitz,&nbsp;Eileen F Dunne,&nbsp;Mona Saraiya,&nbsp;Harrell W Chesson,&nbsp;C Robinette Curtis,&nbsp;Julianne Gee,&nbsp;Joseph A Bocchini,&nbsp;Elizabeth R Unger","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines. Persistent infection with oncogenic HPV types can cause cervical cancer in women as well as other anogenital and oropharyngeal cancers in women and men. HPV also causes genital warts. Two HPV vaccines are licensed in the United States. Both are composed of type-specific HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein using recombinant DNA technology produces noninfectious virus-like particles (VLPs). Quadrivalent HPV vaccine (HPV4) contains four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18. Bivalent HPV vaccine (HPV2) contains two HPV type-specific VLPs prepared from the L1 proteins of HPV 16 and 18. Both vaccines are administered in a 3-dose series. ACIP recommends routine vaccination with HPV4 or HPV2 for females aged 11 or 12 years and with HPV4 for males aged 11 or 12 years. Vaccination also is recommended for females aged 13 through 26 years and for males aged 13 through 21 years who were not vaccinated previously. Males aged 22 through 26 years may be vaccinated. ACIP recommends vaccination of men who have sex with men and immunocompromised persons (including those with HIV infection) through age 26 years if not previously vaccinated. As a compendium of all current recommendations for use of HPV vaccines, information in this report is intended for use by clinicians, vaccination providers, public health officials, and immunization program personnel as a resource. ACIP recommendations are reviewed periodically and are revised as indicated when new information and data become available. </p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":"63 RR-05","pages":"1-30"},"PeriodicalIF":33.7000,"publicationDate":"2014-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).\",\"authors\":\"Lauri E Markowitz,&nbsp;Eileen F Dunne,&nbsp;Mona Saraiya,&nbsp;Harrell W Chesson,&nbsp;C Robinette Curtis,&nbsp;Julianne Gee,&nbsp;Joseph A Bocchini,&nbsp;Elizabeth R Unger\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines. Persistent infection with oncogenic HPV types can cause cervical cancer in women as well as other anogenital and oropharyngeal cancers in women and men. HPV also causes genital warts. Two HPV vaccines are licensed in the United States. Both are composed of type-specific HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein using recombinant DNA technology produces noninfectious virus-like particles (VLPs). Quadrivalent HPV vaccine (HPV4) contains four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18. Bivalent HPV vaccine (HPV2) contains two HPV type-specific VLPs prepared from the L1 proteins of HPV 16 and 18. Both vaccines are administered in a 3-dose series. ACIP recommends routine vaccination with HPV4 or HPV2 for females aged 11 or 12 years and with HPV4 for males aged 11 or 12 years. Vaccination also is recommended for females aged 13 through 26 years and for males aged 13 through 21 years who were not vaccinated previously. Males aged 22 through 26 years may be vaccinated. ACIP recommends vaccination of men who have sex with men and immunocompromised persons (including those with HIV infection) through age 26 years if not previously vaccinated. As a compendium of all current recommendations for use of HPV vaccines, information in this report is intended for use by clinicians, vaccination providers, public health officials, and immunization program personnel as a resource. ACIP recommendations are reviewed periodically and are revised as indicated when new information and data become available. </p>\",\"PeriodicalId\":51328,\"journal\":{\"name\":\"Mmwr Recommendations and Reports\",\"volume\":\"63 RR-05\",\"pages\":\"1-30\"},\"PeriodicalIF\":33.7000,\"publicationDate\":\"2014-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mmwr Recommendations and Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本报告总结了人乳头瘤病毒(HPV)和相关疾病的流行病学,描述了已获许可的HPV疫苗,提供了临床试验和许可后安全性研究的最新数据,并汇编了CDC免疫实践咨询委员会(ACIP)对HPV疫苗使用的建议。持续感染致瘤型人乳头瘤病毒可导致女性宫颈癌以及女性和男性的其他肛门生殖器和口咽癌。HPV也会引起生殖器疣。两种HPV疫苗在美国获得许可。两者都由类型特异性HPV L1蛋白组成,HPV的主要衣壳蛋白。利用重组DNA技术表达L1蛋白可产生非传染性病毒样颗粒(VLPs)。四价HPV疫苗(HPV4)含有由HPV 6、11、16和18的L1蛋白制备的四种HPV类型特异性VLPs。二价HPV疫苗(HPV2)含有由HPV 16和18的L1蛋白制备的两种HPV类型特异性VLPs。这两种疫苗都以3剂系列接种。ACIP建议11岁或12岁的女性常规接种HPV4或HPV2, 11岁或12岁的男性常规接种HPV4。还建议13至26岁的女性和13至21岁以前未接种疫苗的男性接种疫苗。22至26岁的男性可以接种疫苗。ACIP建议,如果以前没有接种过疫苗,对男男性行为者和免疫功能低下者(包括艾滋病毒感染者)接种疫苗至26岁。作为目前所有HPV疫苗使用建议的概要,本报告中的信息旨在供临床医生、疫苗接种提供者、公共卫生官员和免疫规划人员使用。ACIP的建议定期进行审查,并在获得新的信息和数据时进行修订。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).

This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines. Persistent infection with oncogenic HPV types can cause cervical cancer in women as well as other anogenital and oropharyngeal cancers in women and men. HPV also causes genital warts. Two HPV vaccines are licensed in the United States. Both are composed of type-specific HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein using recombinant DNA technology produces noninfectious virus-like particles (VLPs). Quadrivalent HPV vaccine (HPV4) contains four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18. Bivalent HPV vaccine (HPV2) contains two HPV type-specific VLPs prepared from the L1 proteins of HPV 16 and 18. Both vaccines are administered in a 3-dose series. ACIP recommends routine vaccination with HPV4 or HPV2 for females aged 11 or 12 years and with HPV4 for males aged 11 or 12 years. Vaccination also is recommended for females aged 13 through 26 years and for males aged 13 through 21 years who were not vaccinated previously. Males aged 22 through 26 years may be vaccinated. ACIP recommends vaccination of men who have sex with men and immunocompromised persons (including those with HIV infection) through age 26 years if not previously vaccinated. As a compendium of all current recommendations for use of HPV vaccines, information in this report is intended for use by clinicians, vaccination providers, public health officials, and immunization program personnel as a resource. ACIP recommendations are reviewed periodically and are revised as indicated when new information and data become available.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Mmwr Recommendations and Reports
Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
36.00
自引率
0.00%
发文量
3
期刊介绍: The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信